Semler Scientific, Inc.

Good afternoon, and welcome to the Semler Scientific Fourth Quarter 2021 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Before we begin, Semer Scientific would like to remind you that this conference call may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, intend, estimate, or words with similar meanings. And such statements involve a number of risks and uncertainties that could cause Semer Scientific's actual results to differ materially from those discussed here. These risks include continued uncertainty due to the ongoing COVID-19 pandemic, risks associated with Semler Scientific's new distribution arrangement, along with other risks associated with Semler Scientific business. Please note that these forward-looking statements reflect Semler Scientific's opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Please refer to Semler Scientific's SEC filings for a more detailed description of the risk factors that may affect Semler Scientific's results and these forward-looking statements. During the call, Semler Scientific will also discuss certain non-GAAP financial measures, which illustrate the effects of inventory write-down in the fourth quarter on its cost of revenues, earnings per share, basic and diluted, and adjusted income as a percentage of revenues. These non-GAAP financial measures were not prepared in accordance with GAAP and should be considered in addition to and not in lieu of GAAP financial measures. Summer Scientific's press release, which is also available on the Investor Relations section of its website, includes, reconciles the adjustments. Now I'd like to introduce Doug Murphy, Tutorian, CEO of Summer Scientific.

Good afternoon, everyone. Thank you for joining us for the our fourth quarter and year-end results call. I'd like to introduce to you Janice Rosenberg, who is our chief marketing officer, who will begin for us today. Janice?

Thanks, Doug. We always like to begin our calls with a reminder about Semmler's strategy. Semmler is a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Our mission is to develop, manufacture, and market innovative products that assist our customers in evaluating and treating chronic diseases. We believe that our technology and software solutions enable our customers to identify when preventive care options are appropriate, and to intervene before events like heart attacks and strokes occur. We're pleased to report that the company's financial performance during 2021, based on revenue and net income, was the best in our company's history. Comparing results for the year-ended December 31, 2021, to the corresponding period of 2020, the highlights of today's report are as follows. Revenues were higher by 37%, increasing to $53 million. Net income was higher by 23%, increasing to $17.2 million. Cash at the end of the year was $37.3 million, increasing by $15.2 million. Now, Andy Weinstein, our Senior Vice President of Finance and Accounting, will describe our financial performance in more detail. Andy?